MA41785A - Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques - Google Patents

Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques

Info

Publication number
MA41785A
MA41785A MA041785A MA41785A MA41785A MA 41785 A MA41785 A MA 41785A MA 041785 A MA041785 A MA 041785A MA 41785 A MA41785 A MA 41785A MA 41785 A MA41785 A MA 41785A
Authority
MA
Morocco
Prior art keywords
fumarates
compositions
treatment
methods
intravenous administration
Prior art date
Application number
MA041785A
Other languages
English (en)
Inventor
Shyam Karki
Robert Scannevin
Ajay Verma
Fengmei Zheng
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA41785A publication Critical patent/MA41785A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA041785A 2015-03-20 2016-03-17 Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques MA41785A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562136431P 2015-03-20 2015-03-20

Publications (1)

Publication Number Publication Date
MA41785A true MA41785A (fr) 2018-01-23

Family

ID=55702079

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041785A MA41785A (fr) 2015-03-20 2016-03-17 Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques

Country Status (15)

Country Link
US (1) US20180289655A1 (fr)
EP (1) EP3270895A2 (fr)
JP (1) JP2018508559A (fr)
KR (1) KR20170138437A (fr)
CN (1) CN107666905A (fr)
AR (1) AR104029A1 (fr)
AU (1) AU2016235743A1 (fr)
CA (1) CA2979544A1 (fr)
EA (1) EA201792076A1 (fr)
HK (1) HK1244680A1 (fr)
IL (1) IL254576A0 (fr)
MA (1) MA41785A (fr)
MX (1) MX2017012239A (fr)
TW (1) TW201642847A (fr)
WO (1) WO2016153957A2 (fr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
MXPA06002657A (es) * 2003-09-09 2006-06-05 Fumapharm Ag Uso de derivados de acido fumarico para el tratamiento de insuficiencia cardiaca y asma.
CA2478458A1 (fr) 2004-08-20 2006-02-20 Michael Panzara Traitement de la sclerose en plaques pediatrique
EP2801354B1 (fr) * 2004-10-08 2017-02-08 Forward Pharma A/S Compositions pharmaceutiques à libération contrôlée comportant un ester d'acide fumarique
EP1940382A2 (fr) 2005-10-07 2008-07-09 Aditech Pharma AB Polytherapie a base d' esters d' acide fumarique pour le traitement de maladies autoimmunes et/ou inflammatoires
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
EP2680008A1 (fr) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Essais de criblage de Nrf2 et procédés et compositions correspondants
EP2671891A3 (fr) 2008-06-27 2014-03-05 Amgen Inc. Inhibition d'ang-2 pour traiter la sclérose en plaques
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
CN104523673A (zh) 2009-04-29 2015-04-22 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
HUE025878T2 (en) 2010-02-12 2016-05-30 Biogen Ma Inc Neuroprotection in demyelinating diseases
JP5072128B2 (ja) * 2011-03-31 2012-11-14 株式会社ワコール カップ部を有する衣類
US20140308244A1 (en) 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
EP2791181A4 (fr) * 2011-12-16 2015-08-05 Biogen Ma Inc Esters de l'acide fumarique contenant du silicium
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN114146080A (zh) * 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
WO2014031901A1 (fr) 2012-08-22 2014-02-27 Xenoport, Inc. Procédés d'utilisation de fumarate de monométhyle et promédicaments correspondants
TW201436790A (zh) * 2012-12-21 2014-10-01 Biogen Idec Inc 經氘取代之反丁烯二酸酯衍生物類
EP2934507B1 (fr) 2012-12-21 2017-05-31 ratiopharm GmbH Promédicaments du fumarate de monométhyle (mmf)
AU2014205529B2 (en) 2013-01-08 2018-08-09 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2015042294A1 (fr) * 2013-09-18 2015-03-26 Xenoport, Inc. Compositions de nanoparticules de fumarate de diméthyle
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
WO2016074684A1 (fr) * 2014-11-11 2016-05-19 Syddansk Universitet Dérivés d'acide fumarique à usage médical

Also Published As

Publication number Publication date
JP2018508559A (ja) 2018-03-29
TW201642847A (zh) 2016-12-16
AU2016235743A1 (en) 2017-10-12
HK1244680A1 (zh) 2018-08-17
MX2017012239A (es) 2018-06-27
KR20170138437A (ko) 2017-12-15
US20180289655A1 (en) 2018-10-11
WO2016153957A2 (fr) 2016-09-29
CA2979544A1 (fr) 2016-09-29
AR104029A1 (es) 2017-06-21
WO2016153957A3 (fr) 2016-11-10
IL254576A0 (en) 2017-11-30
EP3270895A2 (fr) 2018-01-24
CN107666905A (zh) 2018-02-06
EA201792076A1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
FR23C1008I2 (fr) Compositions d'arni de transthyretine (ttr) et procedes pour les utiliser pour le traitement ou la prevention de maladies associees a ttr
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA43283A (fr) Procédés et compositions pour le traitement du cancer
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
FR3017298B1 (fr) Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
IL264070A (en) Methods and preparations for the treatment of disorders and diseases involving rdh12
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
MA41432A (fr) Composition pharmaceutique pour le traitement de maladies gastro-intestinales
MA41785A (fr) Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
FR3031112B1 (fr) Construction d'adn pour le traitement de pathologies oculaires
MA54511A (fr) Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease